Development of a New HIV Vaccine

Completed · Phase 1

Conditions studied: HIV Infections

In brief

The purpose of the study is to determine the safety of a new HIV vaccine and to evaluate the immune response to the vaccine. Only some HIV genes are used to make the vaccine and therefore the vaccine cannot itself cause HIV or AIDS.

Key facts

Study ID

NCT00051922

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

24

Starts

1997-10-01

Expected to finish

2009-06-01

Last updated by the study team

2011-06-08

Who can join

Age: 18 and older, up to 32. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• HIV-1 negative
• Availability for one year of follow-up
• No evidence of previous smallpox vaccination
• Acceptable methods of contraception

You may not qualify if…

• Immunosuppressive or chronic illness
• Medical or psychological conditions which could affect compliance
• High risk for HIV infection
• Live attenuated vaccines within 60 days
• Experimental agents within 30 days
• Blood products within past 6 months
• Eczema
• Pregnant or lactating women
• Household contact with immunodeficient person, pregnant woman, or child less than 12 months of age
• Allergy to gentamicin

Where it is running

• St. Jude Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.